Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
active, not recruiting

Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD

key information

study id #: NCT02972580

condition: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy

status: active, not recruiting

purpose:

Longitudinal prospective observational study. This is a 24-month study with the possibility of extending the data time points. Initially baseline, then 12 and 24 months follow up studies will be completed.

intervention: Genetic characterization

mechanism of action: No pharmaceutical intervention

results: https://clinicaltrials.gov/ct2/show/results/NCT02972580

last updated: February 04, 2019

study details

start date: June 2016

estimated completion: December 2020

size / enrollment: 250

study description:
Four cohorts are enrolled in this study. The target population is the cohort of genetically confirmed DMD/BMD female carriers (Cohort A). This cohort will consist of 150 DMD/BMD mothers who are somatic carriers of a mutation in the DMD gene. The data collected for this cohort will be compared to three control groups; Control Group B is a cohort of 50 DMD/BMD mothers who are NOT somatic carriers, Control Group C is a cohort of 50 age-matched healthy controls and Control Group D is a cohort of 25 genetically confirmed carriers who do not have an affected child. The inclusion of a Control Group B allows for a comparison to a group of mothers that share the emotional and cognitive burden of caring for an affected male without having the physical or cognitive risks of being a female carrier. The Control Group C offers robust data from an age-matched healthy cohort for purposes of comparison. Control Group D allows for comparison to a group of women that have the same physical or cognitive risks as the Cohort A female carriers, but do not have the same burden of care giving.

primary outcomes:

  • Compromise of cardiac function based on Cardiac Magnetic Resonance Imaging [Time Frame: 2 years]
    Cardiac function as compromised by evidence of scarring of cardiac muscles, particularly of the base of the left ventricle via cardiac MRI studies with gadolinium contrast.

secondary outcomes:

  • Cardiac Function Assessment Treadmill SVO2 [Time Frame: 2 years]
    Stress on heart muscle measured by SVO2 (percentage of oxygen saturation in the blood of the pulmonary artery). SVO2 represents an average of all the venous oxygen saturation of major organs and tissues. This measure provides assessment of cardiopulmonary function and helps measure the degree of cardiac instability and can be an indicator of deterioration from normal.
  • Physical Therapy Assessments Maximum Voluntary Isometric Contraction Testing [Time Frame: 2 Years]
    MVICT measures strength of skeletal muscles by assessing the force generated by by individual muscles. The results can be compared to norms and deterioration can be assessed over time.
  • Physical Therapy Assessments 6 Minute Walk Test [Time Frame: 2 years]
    A timed test to assess distance walked in 6 minutes is very quantitative and can be assessed in comparison to normal controls. Deterioration over time can be clearly measured.
  • Physical Therapy Assessments ACTIVE-seated [Time Frame: 2 Years]
    Exploratory outcome quantifying upper extremity reaching ability using a custom-designed game telling how far the arm reaches in comparison to overall functional ability of the individual ability.
  • Physical Therapy Assessments Time-to-Rise [Time Frame: 2 Years]
    A timed-test to measure ability to rise from the floor is quantifiable and measuring over time tells if there is loss of function.
  • Laboratory biomarkers - Creatine Kinase [Time Frame: 2 Years]
    CK levels are an indicator of muscle breakdown.
  • Laboratory biomarkers - C-Reactive Protein [Time Frame: 2 Years]
    Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown.
  • Laboratory biomarkers - Interleukin-6 [Time Frame: 2 Years]
    Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown.
  • Laboratory biomarkers - Cortisol levels [Time Frame: 2 Years]
    Hair cortisol levels measure stress levels as a means of understanding coping with disease.
  • Cognitive Assessment [Time Frame: 2 Years]
    Cognitive function measured by Wechsler Abbreviated Scale of Intelligence (WASI) provides a possible tool to measure disease awareness and establish if IQ level correlates with disease-related stress.
  • Caregiver Stress [Time Frame: 2 Years]
    Online self-report survey to assess stress burden on caregiver.

inclusion criteria:
• Age >18 years
• Cohort A requires a genetically confirmed mutation in the DMD gene with an affected child
• Cohort B includes DMD/BMD mothers with NO somatic mutation in the DMD gene
• Cohort C age-matched healthy controls with a normal CK level
• Cohort D requires a genetically confirmed mutation in the DMD gene without an affected child
• Able to complete testing in English
• Able to consent

exclusion criteria:
• Subjects with a contraindication to cardiac or skeletal muscle MRI
• Subjects on heart failure medication at time of enrollment
• Subjects on steroid treatment
• Presence of an inherited neurologic disease or comorbidity that may affect their ability to complete this study
• Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's wellbeing, safety, or clinical interpretability

study contacts

sponsor: Nationwide Children's Hospital

investigators: Jerry Mendell, MD

locations: United States